AARTI PHARMALABS LIMITED
Latest filings
Next results: Wed, 28 Oct · Financial Results- Q2 revenue up 46%, PAT up 249%; Rs 574.6 cr stamp duty dispute flagged · Results
- Q2 revenue up 46.8%, PAT up 249%; Rs 57.46 cr stamp duty case; CFO change · Results
- September quarter revenue rises 46%, net profit jumps 249%; stamp duty dispute adds risk · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and Xanthine derivatives at facilities including Tarapur in Maharashtra. Operates a CDMO/CMO business that recorded its highest-ever quarterly revenue of Rs. 155 crore in Q4 FY26. A new manufacturing block at Tarapur Unit 5 adds 3,600 TPA of Xanthine derivatives capacity, taking total Xanthine capacity to 9,600 TPA. Plans to begin R&D investment in peptides and oligonucleotides (TIDES) in FY27 and is building a dedicated CDMO block at Atali with a one-year completion target. Capex was approximately Rs. 400 crore in FY26, with similar levels guided for FY27. Materials make up 45.6% of revenue, the largest cost component, followed by other operating expenses at 24.3% and employee cost at 9.5%.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from AARTI PHARMALABS LIMITED's filed financials and exchange disclosures
What does AARTI PHARMALABS LIMITED do?
AARTI PHARMALABS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AARTIPHARM.
Is AARTI PHARMALABS LIMITED profitable?
Yes. Over the trailing twelve months AARTI PHARMALABS LIMITED reported a net profit of ₹213 Cr on revenue of ₹1,969 Cr.
Does AARTI PHARMALABS LIMITED pay a dividend?
Yes. The dividend yield is 0.45% at the current price. It paid out 21% of its profit as dividend in FY26.
Is AARTI PHARMALABS LIMITED debt-free?
No. It reported borrowings of ₹686 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹677 Cr after cash. Debt stands at 0.32× equity. That is higher than 70% of its 166 Pharmaceuticals peers.
Is AARTI PHARMALABS LIMITED expensive compared with its peers?
On trailing P/E, AARTI PHARMALABS LIMITED ranks 97 of 158 in Pharmaceuticals — cheaper than 39% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the AARTI PHARMALABS LIMITED share price move in a day?
On a typical session AARTI PHARMALABS LIMITED moves 1.51% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are AARTI PHARMALABS LIMITED's next results?
Financial Results on Wed, 28 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track AARTI PHARMALABS LIMITED's announcements?
Every NSE and BSE filing by AARTI PHARMALABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.